Ironwood Pharmaceuticals (IRWD) EBT Margin (2010 - 2026)

Ironwood Pharmaceuticals has disclosed EBT Margin across 17 years of filings, most recently posting 65.23% for Q2 2026.

• In Q2 2026, EBT Margin rose 2085.0% year-over-year to 65.23%; the TTM figure through Jun 2026 stood at 76.67% (up 2974.0% YoY), while the FY2025 annual figure was 54.42%, up 687.0% from the prior year.
• EBT Margin came in at 65.23% for Q2 2026 at Ironwood Pharmaceuticals, up from 61.19% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 191.97% in Q4 2025 to a low of 1002.24% in Q2 2023.
• Average EBT Margin over 5 years is 17.66%, with a median of 55.52% recorded in 2025.
• Year-over-year, EBT Margin sank 105755 bps in 2023 and surged 102223 bps in 2024.
• Over 5 years, EBT Margin stood at 67.41% in 2022, then slumped by 348 bps to 166.88% in 2023, then surged by 183 bps to 139.03% in 2024, then jumped by 38 bps to 191.97% in 2025, then slumped by 66 bps to 65.23% in 2026.
• Per Business Quant data, the three most recent EBT Margin figures were 65.23% in Q2 2026, 61.19% in Q1 2026, and 191.97% in Q4 2025.